These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 23903557)
1. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557 [TBL] [Abstract][Full Text] [Related]
2. Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT. Garcia G; Riera E; Valls E; Soler M; Bassa P; Moragas M; Lomeña F Clin Nucl Med; 2013 Feb; 38(2):120-4. PubMed ID: 23334127 [TBL] [Abstract][Full Text] [Related]
3. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Chakraborty D; Bhattacharya A; Mete UK; Mittal BR Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596 [TBL] [Abstract][Full Text] [Related]
6. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT. Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL; Xue YL; Song HJ; Luo QY Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [TBL] [Abstract][Full Text] [Related]
8. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129 [TBL] [Abstract][Full Text] [Related]
9. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686 [TBL] [Abstract][Full Text] [Related]
10. Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. Shen CT; Qiu ZL; Han TT; Luo QY Clin Nucl Med; 2015 Feb; 40(2):103-10. PubMed ID: 25290289 [TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330 [TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Tateishi U; Morita S; Taguri M; Shizukuishi K; Minamimoto R; Kawaguchi M; Murano T; Terauchi T; Inoue T; Kim EE Ann Nucl Med; 2010 Aug; 24(7):523-31. PubMed ID: 20559896 [TBL] [Abstract][Full Text] [Related]
13. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer]. Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648 [TBL] [Abstract][Full Text] [Related]
14. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis. Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494 [TBL] [Abstract][Full Text] [Related]
15. 18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study. Sharma P; Karunanithi S; Chakraborty PS; Kumar R; Seth A; Julka PK; Bal C; Kumar R Nucl Med Commun; 2014 Dec; 35(12):1247-53. PubMed ID: 25171438 [TBL] [Abstract][Full Text] [Related]
16. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259 [TBL] [Abstract][Full Text] [Related]
17. Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431 [TBL] [Abstract][Full Text] [Related]
19. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Fuccio C; Castellucci P; Schiavina R; Santi I; Allegri V; Pettinato V; Boschi S; Martorana G; Al-Nahhas A; Rubello D; Fanti S Ann Nucl Med; 2010 Jul; 24(6):485-92. PubMed ID: 20544323 [TBL] [Abstract][Full Text] [Related]
20. [Metabolic and osteogenic pattern of prostate cancer bone metastases]. García JR; Riera E; Valls E; Soler M; Moragas M; Lomeña F Rev Esp Med Nucl Imagen Mol; 2013 Jan; 32(1):33-6. PubMed ID: 22835661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]